Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis

Siegel, 2022, Cancer statistics, 2022, CA Cancer J Clin, 72, 7, 10.3322/caac.21708 Karantanos, 2013, Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches, Oncogene, 32, 5501, 10.1038/onc.2013.206 Wade, 2018, Profiling prostate cancer therapeutic resistance, Int J Mol Sci, 19, 904, 10.3390/ijms19030904 Akaza, 2018, Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry, J Glob Oncol, 4, 1 Ritch, 2018, Recent trends in the management of advanced prostate cancer, F1000Res, 7, 1513, 10.12688/f1000research.15382.1 Teo, 2019, Treatment of advanced prostate cancer, Annu Rev Med, 70, 479, 10.1146/annurev-med-051517-011947 Orme, 2022, Rational second-generation antiandrogen use in prostate cancer, Oncologist, 27, 110, 10.1093/oncolo/oyab045 Pfizer, 2019 Nguyen, 2015, Adverse effects of androgen deprivation therapy and strategies to mitigate them, Eur Urol, 67, 825, 10.1016/j.eururo.2014.07.010 Holzbeierlein, 2004, Complications of androgen deprivation therapy: prevention and treatment, Oncology, 18, 303 Nadal, 2014, Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial, Future Oncol, 10, 351, 10.2217/fon.13.275 Janssen, 2018 Astellas, 2019 Shah, 2018, Therapy of advanced prostate cancer: targeting the androgen receptor axis in earlier lines of treatment, Target Oncol, 13, 679, 10.1007/s11523-018-0611-0 Menges, 2022, Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment, Eur Urol Oncol, 5, 605, 10.1016/j.euo.2022.04.007 Mori, 2022, Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis, BJU Int, 129, 423, 10.1111/bju.15507 Wenzel, 2022, Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis, Prostate Cancer Prostat Dis, 25, 139, 10.1038/s41391-021-00395-4 Fizazi, 2019, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol, 20, 686, 10.1016/S1470-2045(19)30082-8 Veroniki, 2016, The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes, J Clin Epidemiol, 76, 193, 10.1016/j.jclinepi.2016.02.016 R Development Core Team, 2021 Sera, 2019, An extended mixed-effects framework for meta-analysis, Stat Med, 38, 5429, 10.1002/sim.8362 Sterne, 2019, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ, 366 Armstrong, 2019, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799 Beer, 2017, Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study, Eur Urol, 71, 151, 10.1016/j.eururo.2016.07.032 Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307 Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0 Fizazi, 2020, Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide, N Engl J Med, 383, 1040, 10.1056/NEJMoa2001342 Penson, 2016, Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial, J Clin Oncol, 34, 2098, 10.1200/JCO.2015.64.9285 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Shore, 2016, Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study, Lancet Oncol, 17, 153, 10.1016/S1470-2045(15)00518-5 Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546 Sternberg, 2020, Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 382, 2197, 10.1056/NEJMoa2003892 Ye, 2017, A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia, Asian J Urol, 4, 75, 10.1016/j.ajur.2017.01.002 Smith, 2022, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N Engl J Med, 386, 1132, 10.1056/NEJMoa2119115 Lin, 2020, Veterans Affairs Cooperative Studies Program study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study, Eur Urol, 77, 563, 10.1016/j.eururo.2019.12.020 Schellhammer, 1997, Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group, Urology, 50, 330, 10.1016/S0090-4295(97)00279-3 Crawford, 1990, Leuprolide with and without flutamide in advanced prostate cancer, Cancer, 66, 1039, 10.1002/cncr.1990.66.s5.1039 Fizazi, 2018, Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer, Clin Genitourin Cancer, 16, 332, 10.1016/j.clgc.2018.07.017 Crawford, 1989, A controlled trial of leuprolide with and without flutamide in prostatic carcinoma, N Engl J Med, 321, 419, 10.1056/NEJM198908173210702 Schellhammer, 1995, A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group, Urology, 45, 745, 10.1016/S0090-4295(99)80077-6 Zhu, 2019, Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis, Cancer Invest, 37, 478, 10.1080/07357907.2019.1670203 Moilanen, 2015, Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies, Sci Rep, 5, 12007, 10.1038/srep12007 Clegg, 2012, ARN-509: a novel antiandrogen for prostate cancer treatment, Cancer Res, 72, 1494, 10.1158/0008-5472.CAN-11-3948 Moreira, 2017, Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials, Oncotarget, 8, 84572, 10.18632/oncotarget.20028 Shore, 2017, Darolutamide (ODM-201) for the treatment of prostate cancer, Expert Opin Pharmacother, 18, 945, 10.1080/14656566.2017.1329820 Chowdhury, 2020, Matching-adjusted indirect comparison of health-related quality of life and adverse events of apalutamide versus enzalutamide in non-metastatic castration-resistant prostate cancer, Adv Ther, 37, 512, 10.1007/s12325-019-01157-4 Ternov, 2021, Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis, Prostate Cancer Prostat Dis, 24, 948, 10.1038/s41391-021-00359-8 Simmonds, 2015, Quantifying the risk of error when interpreting funnel plots, Syst Rev, 4, 24, 10.1186/s13643-015-0004-8 de Souza, 2015, Hypertension in patients with cancer, Arq Bras Cardiol, 104, 246 Zhu, 2022, Risks and management of hypertension in cancer patients undergoing targeted therapy: a review, Clin Hypertens, 28, 14, 10.1186/s40885-022-00197-3 Lee, 2021, Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses, Prostate Cancer Prostat Dis, 24, 244, 10.1038/s41391-020-00275-3 Crona, 2015, Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer, Invest New Drugs, 33, 751, 10.1007/s10637-014-0193-3 Slovin, 2018, Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study, JAMA Oncol, 4, 702, 10.1001/jamaoncol.2017.3361 Ng, 2020, Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting, Oncol Ther, 8, 209, 10.1007/s40487-020-00119-z Laccetti, 2020, A clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: guiding principles for treatment selection and perspectives on research, Onco Targets Ther, 13, 13247, 10.2147/OTT.S242921 López-López, 2018, Dealing with effect size multiplicity in systematic reviews and meta-analyses, Res Synth Methods, 9, 336, 10.1002/jrsm.1310 Sullivan, 2020, Cross-trial comparisons in reviews: proceed with caution, Nat Rev Rheumatol, 16, 663, 10.1038/s41584-020-0492-3 Riley, 2017, Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples, BMJ, 358 Hattle, 2022, Multivariate meta-analysis of multiple outcomes: characteristics and predictors of borrowing of strength from Cochrane reviews, Syst Rev, 11, 149, 10.1186/s13643-022-01999-0 Mavridis, 2013, A practical introduction to multivariate meta-analysis, Stat Methods Med Res, 22, 133, 10.1177/0962280211432219 Zhao, 2022, Empirical comparisons of heterogeneity magnitudes of the risk difference, relative risk, and odds ratio, Syst Rev, 11, 26, 10.1186/s13643-022-01895-7 Felson, 1992, Bias in meta-analytic research, J Clin Epidemiol, 45, 885, 10.1016/0895-4356(92)90072-U Debray, 2018, Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests, Res Synth Methods, 9, 41, 10.1002/jrsm.1266 Austin, 2006, Testing multiple statistical hypotheses resulted in spurious associations: a study of astrological signs and health, J Clin Epidemiol, 59, 964, 10.1016/j.jclinepi.2006.01.012 Efthimiou, 2020, The dark side of the force: multiplicity issues in network meta-analysis and how to address them, Res Synth Methods, 11, 105, 10.1002/jrsm.1377 Jansen, 2011, Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1, Value Health, 14, 417, 10.1016/j.jval.2011.04.002 Mbuagbaw, 2017, Approaches to interpreting and choosing the best treatments in network meta-analyses, Syst Rev, 6, 79, 10.1186/s13643-017-0473-z de Bono, 2020, Olaparib for metastatic castration-resistant prostate cancer, N Engl J Med, 382, 2091, 10.1056/NEJMoa1911440 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Miller, 2021, Combination treatment options for castration-resistant prostate cancer